U.S. Markets open in 7 hrs 59 mins

Palatin Technologies, Inc. (PTN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.6265-0.0035 (-0.5556%)
At close: 3:59PM EDT
People also watch
RNNHEBCVMMSTXCYTR

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4B Cedar Brook Drive
Cranbury, NJ 08512
United States
609-495-2200
http://www.palatin.com

SectorHealthcare
IndustryDiagnostic Substances
Full Time Employees22

Key Executives

NameTitlePayExercisedAge
Dr. John K. A. Prendergast Ph.D.Co-Founder & Chairman95kN/A63
Dr. Carl Spana Ph.D.Co-Founder, Chief Exec. Officer, Pres & Director591kN/A55
Mr. Stephen T. Wills CPA, MSTExec. VP, CFO, COO, Treasurer & Sec.540.77kN/A60
Burns McClellanVP of Investor RelationsN/AN/AN/A
Dr. Johna Lucas M.A., M.D., F.A.C.O.G.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Corporate Governance

Palatin Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.